MA30357B1 - Inhibiteurs du canal ionique task-1 et task-3 - Google Patents
Inhibiteurs du canal ionique task-1 et task-3Info
- Publication number
- MA30357B1 MA30357B1 MA31332A MA31332A MA30357B1 MA 30357 B1 MA30357 B1 MA 30357B1 MA 31332 A MA31332 A MA 31332A MA 31332 A MA31332 A MA 31332A MA 30357 B1 MA30357 B1 MA 30357B1
- Authority
- MA
- Morocco
- Prior art keywords
- disorders
- cancer
- task
- disease
- respiratory
- Prior art date
Links
- 101001050878 Homo sapiens Potassium channel subfamily K member 9 Proteins 0.000 title 1
- 102100024986 Potassium channel subfamily K member 9 Human genes 0.000 title 1
- 229940126181 ion channel inhibitor Drugs 0.000 title 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 3
- 208000023504 respiratory system disease Diseases 0.000 abstract 3
- 206010021143 Hypoxia Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000007954 hypoxia Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000003417 Central Sleep Apnea Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010020591 Hypercapnia Diseases 0.000 abstract 1
- 229940124773 KV1.5 inhibitor Drugs 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010041235 Snoring Diseases 0.000 abstract 1
- 208000034972 Sudden Infant Death Diseases 0.000 abstract 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000006978 adaptation Effects 0.000 abstract 1
- 208000008784 apnea Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000001797 obstructive sleep apnea Diseases 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000009423 ventilation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne l'utilisation des inhibiteurs de Kv1.5 pour la production d'un médicament destiné à la thérapie ou à la prophylaxie des troubles respiratoires, des troubles respiratoires liés au sommeil, des apnées centrales et obstructives du sommeil, du syndrome de résistance des voies aériennes supérieures, de la respiration de Cheyne-Stokes, du ronflement, de l'impulsion respiratoire centrale perturbée, de la mort subite du nourrisson, de l'hypoxie et de l'apnée postopératoires, des troubles respiratoires liés aux muscles, des troubles respiratoires après une ventilation à long terme, des troubles respiratoires pendant l'adaptation en haute montagne, des troubles pulmonaires aigus et chroniques avec hypoxie et hypercapnie, des troubles neurodégénératifs, de la démence, de la maladie d'Alzheimer, de la maladie de Parkinson, de la maladie de Huntington, des troubles du cancer, du cancer du sein, du cancer du poumon, du cancer du colon et du cancer de la prostate.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006019589A DE102006019589A1 (de) | 2006-04-27 | 2006-04-27 | Inhibitoren des TASK-1 und Task-3 Ionenkanals |
| DE102006049527A DE102006049527A1 (de) | 2006-10-20 | 2006-10-20 | Inhibitoren des TASK-1 und TASK-3 Ionenkanals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30357B1 true MA30357B1 (fr) | 2009-04-01 |
Family
ID=38258824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31332A MA30357B1 (fr) | 2006-04-27 | 2008-10-24 | Inhibiteurs du canal ionique task-1 et task-3 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20090149496A1 (fr) |
| EP (1) | EP2012758A2 (fr) |
| JP (1) | JP5161871B2 (fr) |
| KR (1) | KR101390239B1 (fr) |
| CN (1) | CN101636154B (fr) |
| AR (1) | AR060822A1 (fr) |
| AU (1) | AU2007245891B2 (fr) |
| BR (1) | BRPI0710946A2 (fr) |
| CA (1) | CA2650391C (fr) |
| CO (1) | CO6140023A2 (fr) |
| CR (1) | CR10342A (fr) |
| DO (1) | DOP2007000083A (fr) |
| EC (1) | ECSP088847A (fr) |
| GT (1) | GT200800213A (fr) |
| IL (1) | IL194868A (fr) |
| MA (1) | MA30357B1 (fr) |
| MX (1) | MX2008012920A (fr) |
| NO (1) | NO20084513L (fr) |
| NZ (1) | NZ572231A (fr) |
| PE (1) | PE20080061A1 (fr) |
| RU (1) | RU2436577C2 (fr) |
| SG (1) | SG163543A1 (fr) |
| TN (1) | TNSN08431A1 (fr) |
| TW (1) | TWI398432B (fr) |
| UY (1) | UY30313A1 (fr) |
| WO (1) | WO2007124849A2 (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011012712A (es) | 2009-05-29 | 2012-01-30 | Raqualia Pharma Inc | Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio. |
| BRPI1011098A2 (pt) * | 2009-06-03 | 2016-04-12 | Sanofi Aventis Deutschland | fases cristalinas de (2-piridin-3-il-etil)-amida de ácido 2'-{[2-(4-metóxi-fenil)-acetilamino]metil}-bifenil-2-carboxílico. |
| US8664425B2 (en) * | 2010-02-02 | 2014-03-04 | Honeywell International Inc. | Bluegreen fluorescent compounds |
| WO2011103715A1 (fr) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Antagonistes de canal task |
| WO2013037736A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | 4,5,6,7-tétrahydro-1h-pyrazolo[4,3-c]pyridines substituées avec un indanyle, leur utilisation comme médicament, et préparations pharmaceutiques les contenant |
| JP5893143B2 (ja) * | 2011-09-12 | 2016-03-23 | サノフイ | インダニル置換の４，５，６，７−テトラヒドロ−１Ｈ−ピラゾロ［４，３−ｃ］ピリジン、医薬としてのその使用、及びそれらを含む医薬製剤 |
| WO2013037914A1 (fr) | 2011-09-16 | 2013-03-21 | Sanofi | 4,5,6,7-tétrahydro-1h-pyrazolo[4,3-c]pyridines substituées, leur utilisation comme médicament, et préparations pharmaceutiques les contenant |
| EP2755973B1 (fr) | 2011-09-16 | 2015-11-04 | Sanofi | 4,5,6,7-tétrahydro-1h-pyrazolo[4,3-c]pyridines substituées, leur utilisation en tant que médicament et préparations pharmaceutiques les comprenant |
| ES2623167T3 (es) | 2012-02-03 | 2017-07-10 | Sanofi | Pirroldicarboxamidas condensadas y su uso como productos farmacéuticos |
| CN104721832A (zh) * | 2013-12-18 | 2015-06-24 | 深圳先进技术研究院 | 携带编码光敏感离子通道蛋白基因的表达载体在制备调控呼吸节律药物中的应用 |
| AU2016232749B2 (en) * | 2015-03-18 | 2021-09-23 | The Johns Hopkins University | Novel monoclonal antibody inhibitors targeting potassium channel KCNK9 |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| JOP20190005A1 (ar) * | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
| CA3043325A1 (fr) | 2016-11-10 | 2018-05-17 | The Research Foundation For The State University Of New York | Systeme, procede et biomarqueurs d'obstruction des voies aeriennes |
| WO2018119126A1 (fr) * | 2016-12-20 | 2018-06-28 | The University Of Chicago | Dérivés de l-pag pour le traitement de troubles respiratoires du sommeil (sdb) |
| JOP20190148A1 (ar) * | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| JOP20190141A1 (ar) * | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| EP3338803A1 (fr) * | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires |
| EP3338764A1 (fr) * | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires |
| JOP20190284A1 (ar) * | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| TWI903299B (zh) | 2018-03-08 | 2025-11-01 | 美商英塞特公司 | 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物 |
| WO2020010003A1 (fr) | 2018-07-02 | 2020-01-09 | Incyte Corporation | DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ |
| GEP20247606B (en) * | 2018-11-27 | 2024-03-11 | Bayer Ag | Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy |
| CN119462558B (zh) * | 2024-10-18 | 2025-09-19 | 河南中医药大学 | 一种布美他尼衍生物及其制备方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6379666B1 (en) * | 1999-02-24 | 2002-04-30 | Edward L. Tobinick | TNF inhibitors for the treatment of neurological, retinal and muscular disorders |
| DE19929076A1 (de) * | 1999-06-25 | 2000-12-28 | Aventis Pharma Gmbh | Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| US6531495B1 (en) * | 1999-10-02 | 2003-03-11 | Aventis Pharma Deutschland Gmbh | 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them |
| DE19947457A1 (de) * | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen |
| US6716879B2 (en) * | 2000-08-30 | 2004-04-06 | Compass Pharmaceuticals, Llc | Methods for anti-tumor therapy |
| GB2372503A (en) * | 2000-10-19 | 2002-08-28 | Glaxo Group Ltd | Voltage-gated potassium channel polypeptides |
| DE10059418A1 (de) * | 2000-11-30 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10060807A1 (de) * | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10061876A1 (de) * | 2000-12-12 | 2002-06-20 | Aventis Pharma Gmbh | Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10121002A1 (de) * | 2001-04-28 | 2002-11-14 | Aventis Pharma Gmbh | Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10121003A1 (de) * | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10128331A1 (de) * | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| AU2004276267B2 (en) * | 2003-09-23 | 2010-08-19 | Merck Sharp & Dohme Corp. | Isoquinolinone potassium channel inhibitors |
| DE102004009931A1 (de) * | 2004-02-26 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz |
| WO2005085188A2 (fr) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Composes et procedes pour la therapie antitumorale |
| US20080125432A1 (en) * | 2004-12-01 | 2008-05-29 | Devgen Nv | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family |
| DE102005028845A1 (de) * | 2005-06-22 | 2006-12-28 | Sanofi-Aventis Deutschland Gmbh | Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen |
-
2007
- 2007-04-13 KR KR1020087026167A patent/KR101390239B1/ko not_active Expired - Fee Related
- 2007-04-13 MX MX2008012920A patent/MX2008012920A/es active IP Right Grant
- 2007-04-13 JP JP2009506946A patent/JP5161871B2/ja not_active Expired - Fee Related
- 2007-04-13 BR BRPI0710946-6A patent/BRPI0710946A2/pt not_active IP Right Cessation
- 2007-04-13 WO PCT/EP2007/003293 patent/WO2007124849A2/fr not_active Ceased
- 2007-04-13 SG SG201004686-0A patent/SG163543A1/en unknown
- 2007-04-13 NZ NZ572231A patent/NZ572231A/en not_active IP Right Cessation
- 2007-04-13 CA CA2650391A patent/CA2650391C/fr not_active Expired - Fee Related
- 2007-04-13 RU RU2008146755/15A patent/RU2436577C2/ru not_active IP Right Cessation
- 2007-04-13 AU AU2007245891A patent/AU2007245891B2/en not_active Ceased
- 2007-04-13 EP EP07724232A patent/EP2012758A2/fr not_active Withdrawn
- 2007-04-13 CN CN2007800146321A patent/CN101636154B/zh not_active Expired - Fee Related
- 2007-04-25 DO DO2007000083A patent/DOP2007000083A/es unknown
- 2007-04-25 PE PE2007000515A patent/PE20080061A1/es not_active Application Discontinuation
- 2007-04-25 AR ARP070101797A patent/AR060822A1/es unknown
- 2007-04-25 TW TW096114514A patent/TWI398432B/zh not_active IP Right Cessation
- 2007-04-27 UY UY30313A patent/UY30313A1/es unknown
-
2008
- 2008-10-06 CR CR10342A patent/CR10342A/es unknown
- 2008-10-10 GT GT200800213A patent/GT200800213A/es unknown
- 2008-10-15 CO CO08109803A patent/CO6140023A2/es unknown
- 2008-10-16 US US12/252,516 patent/US20090149496A1/en not_active Abandoned
- 2008-10-23 IL IL194868A patent/IL194868A/en not_active IP Right Cessation
- 2008-10-24 EC EC2008008847A patent/ECSP088847A/es unknown
- 2008-10-24 MA MA31332A patent/MA30357B1/fr unknown
- 2008-10-24 TN TNP2008000431A patent/TNSN08431A1/en unknown
- 2008-10-27 NO NO20084513A patent/NO20084513L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30357B1 (fr) | Inhibiteurs du canal ionique task-1 et task-3 | |
| GEP20227366B (en) | Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders | |
| PH12019501408A1 (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| MX2009013211A (es) | Polipeptidos, dominios variables de anticuerpos y antagonistas. | |
| PH12019501458A1 (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| PL1718336T3 (pl) | Nowe połączenie środków antycholinergicznych i beta-mimetyków do leczenia chorób układu oddechowego | |
| MX2011008799A (es) | Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados. | |
| TN2020000021A1 (en) | Substituted diazahetero-bicyclic compounds and their use | |
| TW200708513A (en) | Novel crystalline forms of tiotropium bromide | |
| MY146628A (en) | Novel crystalline anhydride with anticholinergic effect | |
| EP3481345C0 (fr) | Appareil dentaire contre l'apnée du sommeil et les ronflements et pour la réorganisation de la langue et de la cavité buccale | |
| PH12021551186A1 (en) | Process for producing pharmaceutical dosage forms comprising inhibitors of task-1 and task-3 channels and use thereof for therapy of respiratory disorders | |
| SG149876A1 (en) | Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same | |
| MX2009010805A (es) | Metodos y composiciones que comprenden desvenlafaxina o duloxetina para el tratamiento de trastornos de la respiracion relacionados con el sueño. | |
| UA115989C2 (uk) | Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії | |
| UA98460C2 (ru) | Применение ингибиторов ионных task-1 i task-3 каналов | |
| JP2010523662A5 (fr) | ||
| Yoon et al. | Epidemiology and etiology of obstructive sleep apnea | |
| TH91927A (th) | สารยับยั้ง task-1 และ task-3 ไอออนแชนเนล | |
| WO2019098969A3 (fr) | Compositions de poudre sèche à inhaler | |
| AU2006904770A0 (en) | Automatic Positive Airway Pressure Therapy through the nose or mouth for treatment of Sleep Apnea and other respiratory disorders | |
| 稲澤太志 | Effect of Mandibular Position on Upper Airway Collapsibility and Resistance | |
| 王俊隆 et al. | Effects of Combined Long-Acting Beta 2-Agonists and Inhaled Corticosteroids Therapy on Lung Mechanics and Airway Secretion in Prolonged Mechanical Ventilation Patients with Chronic Obstructive Pulmonary Disease | |
| EA201991538A1 (ru) | Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3, и их применение для лечения нарушений дыхания | |
| EA201991540A1 (ru) | Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3 и их применение для лечения нарушений дыхания |